FDA Approves First Implantable Continuous Glucose Monitor

Miriam E. Tucker

Disclosures

June 21, 2018

The US Food and Drug Administration (FDA) has approved the first-ever implantable continuous glucose monitoring system, the Eversense CGM (Senseonics), for people aged 18 years and older with diabetes.

The Eversense CGM

The device consists of a fluorescence-based sensor that is implanted subcutaneously in the upper arm by a physician in a short office procedure, a transmitter worn above the sensor, and a mobile app that displays glucose values and trends and that issues alerts to high and low blood glucose values. The transmitter also issues on-body vibration alerts.

In contrast to current continuous glucose monitors (CGMs) that need to be replaced every 7 to 14 days (typically by patients themselves or caregivers), the Eversense lasts up to 3 months, after which it must be removed in another short office procedure — again by a physician — and replaced on the opposite upper arm.

According to information presented earlier this year at an FDA advisory panel meeting, the Eversense is indicated for adjunctive use, meaning the user still needs to perform fingerstick monitoring for treatment decisions, as well twice-daily calibrations, unlike some other CGMs on the US market.

But the implantation and the long duration of use are aimed at improving patient acceptance of CGMs and increasing the proportion of patients with type 1 diabetes who use the devices, currently only about 25%.

"Research has repeatedly demonstrated the clinical benefits patients experience with regular CGM use, including improved glucose control and protection against severe hypoglycemia," said Steven Edelman, MD, professor of medicine at the University of California, San Diego, in a company statement. "Despite these benefits, a significant number of people with diabetes do not use, or have access to, continuous glucose monitoring."

On March 29 this year, members of the FDA's Clinical Chemistry and Clinical Toxicology Devices Panel voted 8 to 0 with no abstentions for safety, efficacy, and positive benefit/risk for the Eversense. The vote was based on data from the pivotal PRECISE II study, which involved 90 patients with type 1 or type 2 diabetes at eight US centers. Through 90 days, the system performed with an absolute mean relative difference of 8.5% compared with laboratory reference glucose values. The system detected 96% of hypoglycemic excursions and 98% of hyperglycemic excursions, and 91% of the sensors functioned for the entire 90 days.

Potential adverse effects related to insertion, removal, and wear of the sensor include allergic reaction to adhesives, bleeding, bruising, infection, pain or discomfort, scarring or skin discoloration, sensor fracture during removal, skin inflammation, thinning, discoloration, or redness.

Senseonics made some revisions to the product design for safety reasons following PRECISE II, and the current device was tested in only 35 patients in another trial. However, the system has been approved in Europe since May 2016, and users there are being followed in a registry. At the hearing, the FDA advisory panel recommended that the same be done in the United States.

Also at the FDA committee meeting, Seneonics presented its plan for training physicians on how to insert and remove the sensors. Trial investigator Steven J. Russell, MD, from Harvard Medical School in Boston, Massachusetts, said that it was easy to learn and also commented that, as a diabetes-focused endocrinologist, "it's nice to do procedures again."

For more diabetes and endocrinology news, follow us on Twitter and on Facebook

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....